Management of Deep Vein Thrombosis in Special Clinical Scenarios

DVT in Pregnancy and Postpartum

The American College of Chest Physicians recommends using low-molecular-weight heparin (LMWH) as first-line therapy for pregnant women with acute DVT, and continuing anticoagulation for at least 6 weeks postpartum with a minimum total duration of 3 months 1, 2
LMWH is strongly preferred over unfractionated heparin (UFH) for both prevention and treatment of VTE in pregnancy, with a Grade 1B recommendation 1, 3
Warfarin should be avoided during the first trimester due to teratogenicity, with a Grade 1A recommendation, and throughout the second and third trimesters LMWH remains preferred, with a Grade 1B recommendation 1, 3
Direct oral anticoagulants (DOACs) are contraindicated in pregnancy, with a Grade 1C recommendation 1
The American College of Chest Physicians recommends discontinuing LMWH at least 24 hours before planned induction or cesarean section to minimize bleeding risk with neuraxial anesthesia, with a Grade 1B recommendation 4, 5
Continue anticoagulation for at least 6 weeks postpartum, with a minimum total treatment duration of 3 months from diagnosis, with a Grade 2C recommendation 1, 4
Postpartum options include prophylactic- or intermediate-dose LMWH, or warfarin with target INR 2.0-3.0, with a Grade 2B recommendation 4, 5
LMWH, UFH, and warfarin are all safe during breastfeeding and can be continued, with a Grade 1A recommendation for warfarin/UFH and Grade 1B for LMWH 1, 2, 6

The American Society of Clinical Oncology recommends using LMWH as the preferred anticoagulant for patients with DVT and active malignancy, and continuing treatment indefinitely until there is no evidence of active cancer 7
LMWH is preferred over warfarin for cancer-associated thrombosis, with a Grade 2B recommendation 7
Extended anticoagulation is recommended regardless of bleeding risk, with a Grade 2B recommendation 7

In patients with severe renal impairment (CrCl <30 mL/min), dose-adjust LMWH cautiously or consider UFH with aPTT monitoring as an alternative 2, 4
The American College of Chest Physicians recommends dose-reduced LMWH with anti-Factor Xa monitoring, or UFH with aPTT-guided dosing, for patients with CrCl <30 mL/min 2, 4

The American Association for the Study of Liver Diseases recommends using LMWH or UFH with careful monitoring in patients with hepatic impairment, as warfarin dosing becomes unpredictable due to altered vitamin K-dependent clotting factor synthesis 1, 2, 6
Baseline coagulopathy from liver disease does not protect against thrombosis and should not preclude anticoagulation when indicated 6

For patients with recurrent DVT while on therapeutic anticoagulation, verify medication adherence and therapeutic drug levels, then consider increasing anticoagulation intensity or investigating for underlying causes 1, 2, 6, 7
The American College of Chest Physicians recommends screening for occult malignancy, testing for antiphospholipid antibody syndrome, and evaluating for anatomic abnormalities in patients with recurrent DVT despite anticoagulation 1, 7
Consider escalating anticoagulation intensity, such as increasing target INR to 3.0-4.0 for warfarin, or increasing LMWH dose by 25-30% and verifying therapeutic anti-Factor Xa levels 1, 2